Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Osterborg

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|November 19, 2013
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic regionSandra Eketorp Sylvan, Lotta Hansson, Claes Karlsson, et al.
Medical Oncology (Northwood, London, England)|January 7, 2003
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemiaNina Cavalli-Björkman, Eva Osby, Jeanette Lundin, et al.
European Journal of Haematology|October 6, 2007
Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patientsAmir Osman Abdalla, Lotta Hansson, Ingrid Eriksson, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2006
Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemiaAnders Osterborg, Matti Aapro, Paul Cornes, et al.
International Journal of Cancer|October 23, 2004
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemiaAlejo A Morales, Anna Olsson, Fredrik Celsing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignanciesAnders Osterborg, Y Brandberg, V Molostova, et al.
Leukemia & Lymphoma|August 23, 2006
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatmentShahryar Kiaii, Aniruddha Choudhury, Fariba Mozaffari, et al.
British Journal of Haematology|November 20, 2008
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemiaClaes Karlsson, Jeanette Lundin, Eva Kimby, et al.
British Journal of Haematology|February 23, 2007
Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapyAnders Osterborg, Juan Luis Steegmann, Andrzej Hellmann, et al.
Journal of Drug Targeting|September 13, 2015
Ibrutinib-A double-edge sword in cancer and autoimmune disordersParviz Kokhaei, Farhad Jadidi-Niaragh, Abdolreza Sotoodeh Jahromi, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|November 19, 2013
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic regionSandra Eketorp Sylvan, Lotta Hansson, Claes Karlsson, et al.
Medical Oncology (Northwood, London, England)|January 7, 2003
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemiaNina Cavalli-Björkman, Eva Osby, Jeanette Lundin, et al.
European Journal of Haematology|October 6, 2007
Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patientsAmir Osman Abdalla, Lotta Hansson, Ingrid Eriksson, et al.
European Journal of Cancer (Oxford, England : 1990)|December 8, 2006
Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemiaAnders Osterborg, Matti Aapro, Paul Cornes, et al.
International Journal of Cancer|October 23, 2004
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemiaAlejo A Morales, Anna Olsson, Fredrik Celsing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignanciesAnders Osterborg, Y Brandberg, V Molostova, et al.
Leukemia & Lymphoma|August 23, 2006
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatmentShahryar Kiaii, Aniruddha Choudhury, Fariba Mozaffari, et al.
British Journal of Haematology|November 20, 2008
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemiaClaes Karlsson, Jeanette Lundin, Eva Kimby, et al.
British Journal of Haematology|February 23, 2007
Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapyAnders Osterborg, Juan Luis Steegmann, Andrzej Hellmann, et al.
Journal of Drug Targeting|September 13, 2015
Ibrutinib-A double-edge sword in cancer and autoimmune disordersParviz Kokhaei, Farhad Jadidi-Niaragh, Abdolreza Sotoodeh Jahromi, et al.
Pageof 8